Novocure Ltd
NVCR13.440USD
+0.170+1.28%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.51BMarket Cap
LossP/E TTM
More Details of Novocure Ltd Company
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Novocure Ltd Info
Ticker SymbolNVCR
Company nameNovocure Ltd
IPO dateOct 01, 2015
CEOLeonard (Francis X)
Number of employees1488
Security typeOrdinary Share
Fiscal year-endOct 01
AddressNo. 4 The Forum
CitySAINT HELIER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryJersey
Postal codeJE2 4UF
Phone441534756700
Websitehttps://www.novocure.com/
Ticker SymbolNVCR
IPO dateOct 01, 2015
CEOLeonard (Francis X)
Company Executives of Novocure Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
80.44K
-3.73%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
79.14K
-8.16%
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Independent Director
Independent Director
23.41K
+77.43%
Mr. Martin J. Madden
Mr. Martin J. Madden
Independent Director
Independent Director
18.67K
-5.08%
Ms. Kristin Stafford
Ms. Kristin Stafford
Independent Director
Independent Director
14.27K
+252.06%
Dr. Allyson Ocean, M.D.
Dr. Allyson Ocean, M.D.
Independent Director
Independent Director
--
--
Mr. Barak Ben-Arye
Mr. Barak Ben-Arye
General Counsel
General Counsel
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Asaf Danziger
Mr. Asaf Danziger
Director
Director
416.47K
+0.20%
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Executive Chairman of the Board
Executive Chairman of the Board
413.01K
--
Dr. Uri Weinberg, M.D., Ph.D.
Dr. Uri Weinberg, M.D., Ph.D.
Chief Innovation Officer
Chief Innovation Officer
221.22K
+16.80%
Mr. Mukund Paravasthu
Mr. Mukund Paravasthu
Chief Operating Officer
Chief Operating Officer
80.44K
-3.73%
Mr. Christoph Brackmann
Mr. Christoph Brackmann
Chief Financial Officer
Chief Financial Officer
79.14K
-8.16%
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Independent Director
Independent Director
23.41K
+77.43%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
94.26M
59.36%
Germany
19.07M
12.01%
France
18.42M
11.60%
Other EMEA countries
12.98M
8.17%
Japan
9.48M
5.97%
Greater China
4.59M
2.89%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.98%
The Vanguard Group, Inc.
9.32%
Soleus Capital Management, L.P.
8.61%
BlackRock Institutional Trust Company, N.A.
8.03%
Wyss (Hansjorg)
7.27%
Other
51.80%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
14.98%
The Vanguard Group, Inc.
9.32%
Soleus Capital Management, L.P.
8.61%
BlackRock Institutional Trust Company, N.A.
8.03%
Wyss (Hansjorg)
7.27%
Other
51.80%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.56%
Hedge Fund
17.35%
Investment Advisor/Hedge Fund
16.63%
Individual Investor
10.03%
Research Firm
2.34%
Bank and Trust
0.31%
Pension Fund
0.30%
Venture Capital
0.14%
Family Office
0.05%
Other
6.28%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
580
99.65M
89.03%
-8.33M
2025Q2
683
107.66M
96.30%
-11.23M
2025Q1
737
108.90M
97.99%
+1.47M
2024Q4
761
104.07M
94.71%
-2.49M
2024Q3
766
105.53M
97.47%
-2.32M
2024Q2
782
105.08M
97.13%
+3.28M
2024Q1
775
93.94M
87.31%
-7.19M
2023Q4
784
94.40M
88.34%
-2.12M
2023Q3
811
96.26M
90.17%
-961.84K
2023Q2
853
95.14M
89.25%
-1.89M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
16.72M
14.96%
+235.48K
+1.43%
Jun 30, 2025
The Vanguard Group, Inc.
10.73M
9.6%
-499.10K
-4.45%
Jun 30, 2025
Soleus Capital Management, L.P.
6.90M
6.18%
+1.38M
+25.05%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.99M
8.04%
+204.02K
+2.32%
Jun 30, 2025
Wyss (Hansjorg)
8.14M
7.28%
--
--
Apr 04, 2025
BlackRock Financial Management, Inc.
2.73M
2.44%
+665.88K
+32.30%
Jun 30, 2025
State Street Investment Management (US)
2.68M
2.4%
+89.36K
+3.45%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.44M
2.19%
-19.15K
-0.78%
Jun 30, 2025
Capital World Investors
6.38M
5.71%
+1.17M
+22.38%
Jun 30, 2025
Nuveen LLC
1.01M
0.9%
+325.33K
+47.58%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
State Street SPDR S&P Health Care Equipment ETF
1.88%
ROBO Global Healthcare Technology & Innovation ETF
1.72%
Global X HealthTech ETF
1.29%
Amplify BlueStar Israel Technology ETF
0.61%
iShares Health Innovation Active ETF
0.4%
VanEck Israel ETF
0.24%
Global X Aging Population ETF
0.22%
iShares U.S. Medical Devices ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
View more
State Street SPDR S&P Health Care Equipment ETF
Proportion1.88%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.72%
Global X HealthTech ETF
Proportion1.29%
Amplify BlueStar Israel Technology ETF
Proportion0.61%
iShares Health Innovation Active ETF
Proportion0.4%
VanEck Israel ETF
Proportion0.24%
Global X Aging Population ETF
Proportion0.22%
iShares U.S. Medical Devices ETF
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.14%
Invesco Nasdaq Biotechnology ETF
Proportion0.14%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Novocure Ltd?
The top five shareholders of Novocure Ltd are:
Fidelity Management & Research Company LLC holds 16.72M shares, accounting for 14.96% of the total shares.
The Vanguard Group, Inc. holds 10.73M shares, accounting for 9.60% of the total shares.
Soleus Capital Management, L.P. holds 6.90M shares, accounting for 6.18% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.99M shares, accounting for 8.04% of the total shares.
Wyss (Hansjorg) holds 8.14M shares, accounting for 7.28% of the total shares.
Fidelity Management & Research Company LLC holds 16.72M shares, accounting for 14.96% of the total shares.
The Vanguard Group, Inc. holds 10.73M shares, accounting for 9.60% of the total shares.
Soleus Capital Management, L.P. holds 6.90M shares, accounting for 6.18% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 8.99M shares, accounting for 8.04% of the total shares.
Wyss (Hansjorg) holds 8.14M shares, accounting for 7.28% of the total shares.
What are the top three shareholder types of Novocure Ltd?
The top three shareholder types of Novocure Ltd are:
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Soleus Capital Management, L.P.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Soleus Capital Management, L.P.
How many institutions hold shares of Novocure Ltd (NVCR)?
As of 2025Q3, 580 institutions hold shares of Novocure Ltd, with a combined market value of approximately 99.65M, accounting for 89.03% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.27%.
What is the biggest source of revenue for Novocure Ltd?
In FY2025Q2, the -- business generated the highest revenue for Novocure Ltd, amounting to -- and accounting for --% of total revenue.
